Terumo stock analysis
Terumo (TRUMF) Stock Price & Analysis
TRUMF Stock Chart & Stats
- Day’s Range
- $15.33 - $16.28
- 52-Week Range
- $11.49 - $17.69
- Previous Close
- $15.82
- Volume
- N/A
- Average Volume (3M)
- 225
- Market Cap
- $23.22B
- Enterprise Value
- $3.37T
- Total Cash (Recent Filing)
- $314.63B
- Total Debt (Recent Filing)
- $389.46B
- Price to Earnings (P/E)
- 22.9
- Beta
- 0.53
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 0.11
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 1.32%
Bulls Say, Bears Say
Bulls Say
Resilient Profitability
Terumo’s strong gross, operating, EBITDA, and net margins indicate a profitable medical-technology platform with meaningful earnings capacity. This profitability can support continued investment in product development, regulatory execution, and commercial expansion while providing resilience across normal procedure and procurement cycles.
Recurring Clinical Demand And Global Positions
Terumo benefits from recurring demand for procedure devices, blood-management systems, and everyday hospital consumables that require replenishment. Established global positions in key products further support customer familiarity, distribution reach, and durable revenue generation across clinical workflows.
Portfolio Expansion And Structural Growth Opportunities
The Arsenal acquisition broadens Terumo Neuro into chronic subdural hematoma treatment, while rapid Organ Technologies growth adds exposure to expanding organ-preservation applications. These initiatives diversify the portfolio and create additional avenues for durable growth beyond established categories.
Bears Say
Aortic Recall And Unresolved Production Issue
The unresolved Aortic quality issue creates a continuing operational and commercial overhang because shipments remain suspended and corrective actions are incomplete. Uncertain recovery timing can disrupt customer relationships, delay revenue normalization, and require further resources before the business returns to stable execution.
CSL Plasma Termination And Impairment Exposure
The CSL Plasma agreement termination has already produced substantial impairment and related charges, while the business is expected to scale down. This reduces contribution from the affected activity, signals a material portfolio reset, and can weigh on near-term earnings quality and capital efficiency.
Slower Growth And Mixed Cash Conversion
Recent revenue growth has decelerated materially from earlier expansion, suggesting a more mature growth phase or tougher comparisons. At the same time, free-cash-flow conversion and operating-cash coverage of debt are mixed, which may constrain internally funded investment and reduce financial flexibility.
TRUMF FAQ
What was Terumo’s price range in the past 12 months?
What is Terumo’s market cap?
When is Terumo’s upcoming earnings report date?
How were Terumo’s earnings last quarter?
Is Terumo overvalued?
Does Terumo pay dividends?
What is Terumo’s EPS estimate?
How many shares outstanding does Terumo have?
What happened to Terumo’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Terumo?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Terumo
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Hikaru Samejima
- Employees
- 31,185
- Website
- www.terumo.com
- Address
- 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP
Terumo (TRUMF) Earnings & Revenues
TRUMF Company Deck
TRUMF Earnings Call
Earnings Call SentimentNeutral
The call reflected strong underlying operating momentum, including record first-half revenue and adjusted operating profit, broad core-business growth, and positive long-term initiatives in TBCT, Neuro, Organ Technologies, and CDMO. However, the sentiment was tempered by the Terumo Aortic recall, unresolved manufacturing issues, substantial asset-valuation and impairment risks, the CSL Plasma agreement termination, temporary Neuro supply constraints, and significant reductions to reported operating-profit and revenue guidance. Overall, the positive core-business performance and adjusted-profit growth were balanced by material one-time charges and operational uncertainty.
View all TRUMF earnings summariesTRUMF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 10 | 0 | 2 |
